Blood
Journal Abbreviation: BLOOD
ISSN: 0006-4971
eISSN: 1528-0020
Publisher: American Society of Hematology
Publications (151)
CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome (2022)
Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, Krug U, et al.
Journal article
A CMV seronegative donor to avoid T-cell inflation? (2021)
Einsele H, Doelken L
Journal article
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma (2021)
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, et al.
Journal article
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 (2021)
Kayser S, Martinez-Cuadron D, Hanoun M, Stoelzel F, Gil C, Reinhardt HC, Aguiar E, et al.
Conference contribution
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia (2021)
Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al.
Conference contribution
Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis (2021)
Dreger P, Schubert ML, Holtick U, Subklewe M, Von Bastian T, Ayuk FA, Wagner EM, et al.
Conference contribution
Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis (2021)
Bethge WA, Martus P, Schmitt M, Holtick U, Borchmann P, Subklewe M, Rejeski K, et al.
Conference contribution
Prognostic Value of Elafin in Acute Graft-Versus-Host Disease (2021)
Zewde MG, Morales G, Gandhi I, Ozbek U, Aguayo-Hiraldo P, Ayuk FA, Baez J, et al.
Conference contribution
Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience (2021)
Enssle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al.
Conference contribution
Allogeneic Hematopoietic Cell Transplantation in Patients <= 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial- (2021)
Bornhaeuser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, Platzbecker U, et al.
Conference contribution